Predicting cognitive stage transition using p‐tau181, Centiloid, and other measures

BACKGROUND A combination of plasma phospho-tau (p-tau), amyloid beta (Aβ)-positron emission tomography (PET), brain magnetic resonance imaging, cognitive function tests, and other biomarkers might predict future cognitive decline. This study aimed to investigate the efficacy of combining these biomarkers in predicting future cognitive stage transitions within 3 years. METHODS Among the participants in the Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease (KBASE-V) study, 49 mild cognitive impairment (MCI) and 113 cognitively unimpaired (CU) participants with Aβ-PET and brain imaging data were analyzed. RESULTS Older age, increased plasma p-tau181, Aβ-PET positivity, and decreased semantic fluency were independently associated with cognitive stage transitions. Combining age, p-tau181, the Centiloid scale, semantic fluency, and hippocampal volume produced high predictive value in predicting future cognitive stage transition (area under the curve = 0.879). CONCLUSIONS Plasma p-tau181 and Centiloid scale alone or in combination with other biomarkers, might predict future cognitive stage transition in non-dementia patients. HIGHLIGHTS -Plasma p-tau181 and Centiloid scale might predict future cognitive stage transition. -Combining them or adding other biomarkers increased the predictive value. -Factors that independently associated with cognitive stage transition were demonstrated.

[1]  S. Moon,et al.  Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update , 2022, Journal of clinical neurology.

[2]  F. Barkhof,et al.  Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease , 2022, The Journal of Prevention of Alzheimer's Disease.

[3]  Hee Jin Kim,et al.  Serum neurofilament light chain level as a predictor of cognitive stage transition , 2022 .

[4]  W. Borelli,et al.  Amyloid-β PET Classification on Cognitive Aging Stages Using the Centiloid Scale , 2021, Molecular Imaging and Biology.

[5]  K. Blennow,et al.  Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: a focused review on recent advances , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  K. Blennow,et al.  Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  K. Blennow,et al.  Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures , 2021, Nature Medicine.

[8]  R. Lhommel,et al.  Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  B. Yoon,et al.  Telomere shortening reflecting physical aging is associated with cognitive decline and dementia conversion in mild cognitive impairment due to Alzheimer’s disease , 2020, Aging.

[10]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[11]  C. Rowe,et al.  Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[12]  Si Eun Kim,et al.  Association of Nutritional Status with Cognitive Stage in the Elderly Korean Population: The Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease , 2019, Journal of clinical neurology.

[13]  K. Blennow,et al.  Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers , 2019, Alzheimer's Research & Therapy.

[14]  D. Y. Lee,et al.  Clinical and Biomarker Characteristics According to Clinical Spectrum of Alzheimer’s Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the Early Diagnosis and Prediction of AD , 2019, Journal of clinical medicine.

[15]  Ranjan Duara,et al.  Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment , 2018, JAMA neurology.

[16]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[17]  B. Lee,et al.  Re-standardization of the Korean-Instrumental Activities of Daily Living (K-IADL): Clinical Usefulness for Various Neurodegenerative Diseases , 2018, Dementia and neurocognitive disorders.

[18]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[19]  K. Blennow,et al.  CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease , 2016, Annals of clinical and translational neurology.

[20]  Danielle J. Harvey,et al.  The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding , 2015, Alzheimer's & Dementia.

[21]  Robert A. Koeppe,et al.  The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.

[22]  Paul Maruff,et al.  Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease , 2013, Alzheimer's & Dementia.

[23]  A. Dahan,et al.  Using Akaike's information theoretic criterion in mixed-effects modeling of pharmacokinetic data: a simulation study , 2013, F1000Research.

[24]  Stephen M. Smith,et al.  A Bayesian model of shape and appearance for subcortical brain segmentation , 2011, NeuroImage.

[25]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[26]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[27]  Alan C. Evans,et al.  Automated 3-D extraction and evaluation of the inner and outer cortical surfaces using a Laplacian map and partial volume effect classification , 2005, NeuroImage.

[28]  David R. Anderson,et al.  Multimodel Inference , 2004 .

[29]  Jae Nam Bae,et al.  Development of the Korean version of the Geriatric Depression Scale and its short form among elderly psychiatric patients. , 2004, Journal of psychosomatic research.

[30]  Ki Woong Kim,et al.  A normative study of the CERAD neuropsychological assessment battery in the Korean elderly , 2004, Journal of the International Neuropsychological Society.

[31]  B. Lee,et al.  Interchanging Scores Between Clinical Dementia Rating Scale and Global Deterioration Scale , 2003, Alzheimer disease and associated disorders.

[32]  Stephen M Smith,et al.  Fast robust automated brain extraction , 2002, Human brain mapping.

[33]  Alan C. Evans,et al.  Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis , 2002, IEEE Transactions on Medical Imaging.

[34]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[35]  Alan C. Evans,et al.  Measurement of Cortical Thickness Using an Automated 3-D Algorithm: A Validation Study , 2001, NeuroImage.

[36]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[37]  D. Collins,et al.  Automatic 3D Intersubject Registration of MR Volumetric Data in Standardized Talairach Space , 1994, Journal of computer assisted tomography.

[38]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.